摘要
Chimeric antigen receptor T cell (CAR-T) therapy has emerged as highly effective in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but only about 40% patients have achieved sustained responses. Here, we conducted a phase II clinical trial testing efficacy and toxicities of CAR-T therapy in R/R non-Hodgkin's lymphoma patients (NCT03196830). Among enrolled patients, 33 R/R DLBCL patients pretreated with DFC (decitabine, fludarabine plus cyclophosphamide) lymphodepletion chemotherapy and infused with tandem CD19-CD22 based CAR-T cells were drawn out for efficacy and toxicities of CAR-T therapy evaluation. With a median follow-up of 10.9(0.6-29.0) months, the best overall response and complete remission (CR) rates were 90.9% and 63.6%, respectively. The median progression-free survival (PFS) was 10.2 months and overall survival (OS) was undefined. The 2-year OS and PFS rates were 54.3% and 47.2%, respectively. No severe grade 4 cytokine release syndrome (CRS) was observed and grade 3 CRS was observed in only 7 patients; 3 patients developed mild immune effect or cell-associated neurotoxic syndrome. All toxicities were transient and reversible and no CAR-T-related mortality. Further subgroup analysis showed that achieving CR was an independent prognostic factor associated with favorable PFS and OS. The 2-year OS and PFS for patients who achieved CR within 3 months (undefined versus undefined P=0.021 and undefined versus undefined P=0.036) or during the follow-up period were significantly longer than those who did not (undefined versus 4.6 months P < 0.0001 and undefined versus 2.0months P<0.001). While severe CRS was also an independent prognostic factor but associated with inferior PFS and OS. The 2-year OS and PFS for patients with grade 3 CRS were significantly shorter than those with grade 0-2 CRS (4.1 months versus undefined PP=0.0002). This study indicated that CD19/CD22 dual-targeted CAR-T therapy under a decitabine-containing lymphodepletion regimen may be a safe, potent effective approach to R/R DLBCL patients.
学科与关键词
- Tislelizumab augment the efficacy of CD19/22 dual-targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B-cell non-Hodgkin lymphomaZhang, Ying; Geng, Hongzhi; Zeng, Liangyu; Li, Jiaqi; Yang, Qin; Jia, Sixun; Zong, Xiangping; Cai, Wenzhi; Liu, Shuangzhu; Lu, Yutong; Yu, Lei; Li, Caixia*; Wu, Depei*Hematological Oncology, 2023.
- CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphomaCheng, Qian; Tan, Jingwen; Liu, Rui; Kang, Liqing; Zhang, Yi; Wang, Erhua; Li, Ying; Zhang, Jian; Xiao, Han; Xu, Nan; Li, Minghao; Yu, Lei*; Li, Xin*CYTOTHERAPY, 2022, 24(10): 1026-1034.被引 9
- Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphomaPing, Nana; Qu, Changju; Li, Mengyun; Kang, Liqing; Kong, Danqin; Chen, Xiaochen; Wu, Qian; Xia, Fan; Yu, Lei; Yao, Hong; Yan, Lingzhi; Wu, Depei*; Jin, Zhengming*Annals of Translational Medicine, 2022, 10(6).被引 4
